Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRDS Pardes Biosciences (PRDS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Pardes Biosciences Stock (NASDAQ:PRDS) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Pardes Biosciences alerts:Sign Up Key Stats Today's Range$2.16▼$2.1650-Day Range$2.13▼$2.1652-Week Range$0.75▼$3.93Volume400 shsAverage Volume359,530 shsMarket Capitalization$133.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.Read More… The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Receive PRDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PRDS Stock News HeadlinesPardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo WeatherOctober 31, 2023 | yahoo.comPardes Biosciences Announces Closing of Tender OfferAugust 31, 2023 | finance.yahoo.comThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.November 4, 2024 | Porter & Company (Ad)MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesAugust 28, 2023 | finance.yahoo.comMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesAugust 17, 2023 | finance.yahoo.comPardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28August 3, 2023 | msn.comPardes Biosciences Shares Rise 15% After Buyout Offer From MediPacificJuly 19, 2023 | marketwatch.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)July 19, 2023 | markets.businessinsider.comSee More Headlines PRDS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pardes Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pardes Biosciences investors own include Meta Platforms (META), Valneva (VALN), Arcturus Therapeutics (ARCT), Apellis Pharmaceuticals (APLS), Annexon (ANNX), ANI Pharmaceuticals (ANIP) and AnaptysBio (ANAB). Company Calendar Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PRDS CUSIPN/A CIK1822711 Webwww.pardesbio.com Phone415-649-8758FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.36% Return on Assets-40.71% Debt Debt-to-Equity RatioN/A Current Ratio81.72 Quick Ratio81.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.51 per share Price / Book0.86Miscellaneous Outstanding Shares62,012,000Free Float36,711,000Market Cap$133.95 million OptionableNot Optionable Beta0.42 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:PRDS) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pardes Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pardes Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
